XML 79 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Indirect Cash Flow (Details) - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Jun. 17, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Supplemental Cash Flow Elements [Abstract]          
Net income (loss) $ 1,077,069 $ 624,885 $ 1,241,201 $ 1,701,954 $ 2,461,419
Adjustments to reconcile consolidated net income to net cash provided by operating activities:          
Income from financial royalty assets     (2,065,083) (1,959,975) (1,648,837)
Provision for changes in expected cash flows from financial royalty assets     452,842 230,839 (1,019,321)
Amortization of intangible assets     22,996 23,058 23,924
Amortization of debt discount and issuance costs     20,162 11,715 12,790
Losses on derivative financial instruments     21,532 42,076 39,138
Losses/(gains) on equity securities     48,066 (247,073) (155,749)
Equity in losses/(earnings) of non-consolidated affiliates     19,490 (44,459) 32,517
Distributions from non-consolidated affiliates     34,384 42,334 14,059
Loss on extinguishment of debt     358 30,272 0
Share-based compensation     2,443 5,428 0
Interest income accretion     (50,896) (20,551) 0
Unrealized gains on available for sale debt securities     (17,859) (18,600) 0
Impairment charge     0 65,053 0
Termination of derivative financial instruments     (16,093) (34,952) 0
Other     4,461 9,621 (2,122)
Decrease/(increase) in operating assets:          
Cash collected on financial royalty assets     2,315,854 2,121,923 1,934,092
Available for sale debt securities     0 0 (150,000)
Accrued royalty receivable     (20,131) 370 2,471
Other receivables     0 0 150,000
Other royalty income receivable     (9,012) (770) 7,390
Other current assets and other assets     1,857 34,986 (41,028)
(Decrease)/increase in operating liabilities:          
Accounts payable and accrued expenses     (4,586) (766) 6,496
Interest payable     15,550 42,146 0
Net cash provided by operating activities     2,017,536 2,034,629 1,667,239
Supplemental Schedule of Non-cash Investing/Financing Activities:          
Receipt of contribution of investments in Legacy Investors Partnerships     0 303,679 0
Settlement of Epizyme forward purchase contract     0 5,700 0
Accrued purchase obligation - Tazverik     0 110,000 0
Repayments of long-term debt by contributions from non-controlling interest     0 1,103,774 0
Milestone payable - Erleada     $ 0 $ 18,600 $ 0